Last reviewed · How we verify
Period I : CJ30001, Period II : HKB0701 and SLM0807 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Period I : CJ30001, Period II : HKB0701 and SLM0807 (Period I : CJ30001, Period II : HKB0701 and SLM0807) — HK inno.N Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Period I : CJ30001, Period II : HKB0701 and SLM0807 TARGET | Period I : CJ30001, Period II : HKB0701 and SLM0807 | HK inno.N Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Period I : CJ30001, Period II : HKB0701 and SLM0807 CI watch — RSS
- Period I : CJ30001, Period II : HKB0701 and SLM0807 CI watch — Atom
- Period I : CJ30001, Period II : HKB0701 and SLM0807 CI watch — JSON
- Period I : CJ30001, Period II : HKB0701 and SLM0807 alone — RSS
Cite this brief
Drug Landscape (2026). Period I : CJ30001, Period II : HKB0701 and SLM0807 — Competitive Intelligence Brief. https://druglandscape.com/ci/period-i-cj30001-period-ii-hkb0701-and-slm0807. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab